Insider Transactions in Q4 2024 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,283
-7.23%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,283
-5.96%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,591
-0.7%
|
$20,728
$8.06 P/Share
|
|
Dec 06
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
866
-4.61%
|
$6,928
$8.06 P/Share
|
|
Dec 06
2024
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
5,142
-0.64%
|
$41,136
$8.06 P/Share
|
|
Dec 06
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
2,591
-2.75%
|
$20,728
$8.06 P/Share
|
|
Dec 01
2024
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.93%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-0.43%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-2.33%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-1.66%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,829
-0.47%
|
$30,632
$8.6 P/Share
|